clinical trials

Momentum Builds Across Biotech Pipeline: Seizure Breakthrough, Cell Therapy Revival, and Obesity Medicine Gains

Momentum Builds Across Biotech Pipeline: Seizure Breakthrough, Cell Therapy Revival, and Obesity Medicine Gains

The biotechnology sector experienced significant positive developments this week, with Xenon Pharmaceuticals' seizure medication achieving a decisive late-stage victory while regulatory pathways accelerated for several other promising therapies. According to…

Continue Reading Momentum Builds Across Biotech Pipeline: Seizure Breakthrough, Cell Therapy Revival, and Obesity Medicine Gains
Breakthrough DNA Repair Inhibitor Advances Rapidly Toward Clinic: Artios’ ART6043 Earns FDA Fast Track Status for Resistant Breast Cancer

Breakthrough DNA Repair Inhibitor Advances Rapidly Toward Clinic: Artios’ ART6043 Earns FDA Fast Track Status for Resistant Breast Cancer

Artios Pharma has achieved a significant milestone in cancer treatment development with the U.S. Food and Drug Administration's granting of Fast Track designation to ART6043, a potentially first-in-class DNA polymerase…

Continue Reading Breakthrough DNA Repair Inhibitor Advances Rapidly Toward Clinic: Artios’ ART6043 Earns FDA Fast Track Status for Resistant Breast Cancer
Bristol Myers Squibb Reports Positive Phase 3 Data for Mezigdomide-Based Oral Regimen in Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb Reports Positive Phase 3 Data for Mezigdomide-Based Oral Regimen in Relapsed or Refractory Multiple Myeloma

As reported on drugs.com, Bristol Myers Squibb (BMS) has announced encouraging interim results from the Phase 3 portion of the SUCCESSOR-2 clinical trial evaluating oral mezigdomide in patients with relapsed…

Continue Reading Bristol Myers Squibb Reports Positive Phase 3 Data for Mezigdomide-Based Oral Regimen in Relapsed or Refractory Multiple Myeloma
Daiichi Sankyo Advances Enhertu for High-Risk Breast Cancer: New Hope After Neoadjuvant Therapy

Daiichi Sankyo Advances Enhertu for High-Risk Breast Cancer: New Hope After Neoadjuvant Therapy

Daiichi Sankyo has taken a significant step forward in expanding treatment options for early-stage breast cancer patients by submitting a supplemental New Drug Application (sNDA) to Japan's Ministry of Health,…

Continue Reading Daiichi Sankyo Advances Enhertu for High-Risk Breast Cancer: New Hope After Neoadjuvant Therapy
Vico Therapeutics Begins Twice‑Yearly Dosing of VO659 in Phase 1/2 Trial for Huntington’s Disease and Spinocerebellar Ataxias

Vico Therapeutics Begins Twice‑Yearly Dosing of VO659 in Phase 1/2 Trial for Huntington’s Disease and Spinocerebellar Ataxias

As reported in Business Wire, Vico Therapeutics has initiated patient dosing in an expanded cohort of its Phase 1/2a clinical study evaluating VO659, an antisense oligonucleotide (ASO) designed to target…

Continue Reading Vico Therapeutics Begins Twice‑Yearly Dosing of VO659 in Phase 1/2 Trial for Huntington’s Disease and Spinocerebellar Ataxias
FDA Approves Revolutionary Oral Combination Therapy for Chronic Lymphocytic Leukemia, Offering Patients Freedom from Long-Term Treatment

FDA Approves Revolutionary Oral Combination Therapy for Chronic Lymphocytic Leukemia, Offering Patients Freedom from Long-Term Treatment

AbbVie has announced a landmark regulatory milestone with the US FDA's approval of a supplemental new drug application (sNDA) for the combination of Venclexta (venetoclax) and acalabrutinib as a first-line…

Continue Reading FDA Approves Revolutionary Oral Combination Therapy for Chronic Lymphocytic Leukemia, Offering Patients Freedom from Long-Term Treatment
Breakthrough in Rare Bone Disease: FDA Fast-Tracks Garetosmab for Fibrodysplasia Ossificans Progressiva

Breakthrough in Rare Bone Disease: FDA Fast-Tracks Garetosmab for Fibrodysplasia Ossificans Progressiva

Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the Biologics License Application (BLA) for garetosmab, marking a significant milestone for patients living with…

Continue Reading Breakthrough in Rare Bone Disease: FDA Fast-Tracks Garetosmab for Fibrodysplasia Ossificans Progressiva
Once-Daily Zasocitinib Delivers Clear Skin for Psoriasis Patients: Takeda’s Landmark Phase 3 Victory

Once-Daily Zasocitinib Delivers Clear Skin for Psoriasis Patients: Takeda’s Landmark Phase 3 Victory

Takeda Pharmaceutical Company has announced breakthrough results from Phase 3 trials of zasocitinib (TAK-279), an innovative oral treatment for moderate-to-severe plaque psoriasis that offers patients a promising new option for…

Continue Reading Once-Daily Zasocitinib Delivers Clear Skin for Psoriasis Patients: Takeda’s Landmark Phase 3 Victory
FibroBiologics Advances Innovative Cell Therapy: FDA Review of CYPS317 for Psoriasis Treatment Marks Major Clinical Milestone

FibroBiologics Advances Innovative Cell Therapy: FDA Review of CYPS317 for Psoriasis Treatment Marks Major Clinical Milestone

FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to the US Food and Drug…

Continue Reading FibroBiologics Advances Innovative Cell Therapy: FDA Review of CYPS317 for Psoriasis Treatment Marks Major Clinical Milestone
Pemvidutide Shows Sustained Weight Loss and Liver Improvement in Extended MASH Trial Data

Pemvidutide Shows Sustained Weight Loss and Liver Improvement in Extended MASH Trial Data

Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating continued weight loss and…

Continue Reading Pemvidutide Shows Sustained Weight Loss and Liver Improvement in Extended MASH Trial Data
Deucrictibant Provides Rapid Relief for Hereditary Angioedema Attack Symptoms

Deucrictibant Provides Rapid Relief for Hereditary Angioedema Attack Symptoms

A new oral medication has demonstrated remarkable effectiveness in treating hereditary angioedema (HAE) attacks, offering patients significantly faster symptom relief compared to existing options. According to Healio.com, the RAPIDe-3 study…

Continue Reading Deucrictibant Provides Rapid Relief for Hereditary Angioedema Attack Symptoms
Gilead’s Dual-Action HIV Breakthrough: Single-Tablet Bictegravir-Lenacapavir Regimen Shows Promise in Phase 3 Trial

Gilead’s Dual-Action HIV Breakthrough: Single-Tablet Bictegravir-Lenacapavir Regimen Shows Promise in Phase 3 Trial

Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial on December 15, 2025 and reported by Drugs.com, marking a significant advancement in HIV treatment options. The trial…

Continue Reading Gilead’s Dual-Action HIV Breakthrough: Single-Tablet Bictegravir-Lenacapavir Regimen Shows Promise in Phase 3 Trial
Biotech Innovation Accelerates: Four Companies Show Promising Pipeline Progress

Biotech Innovation Accelerates: Four Companies Show Promising Pipeline Progress

The biotech sector witnessed significant momentum as four clinical-stage companies announced compelling data across muscular dystrophy, immunology, and obesity treatment areas, triggering substantial stock market gains and investor enthusiasm for…

Continue Reading Biotech Innovation Accelerates: Four Companies Show Promising Pipeline Progress
Giredestrant Emerges as Breakthrough Adjuvant Therapy for Early-Stage ER-Positive Breast Cancer

Giredestrant Emerges as Breakthrough Adjuvant Therapy for Early-Stage ER-Positive Breast Cancer

Genentech announced landmark clinical trial results demonstrating that giredestrant, an investigational selective estrogen receptor degrader (SERD), significantly outperforms standard endocrine therapy in treating early-stage ER-positive breast cancer. As reported by…

Continue Reading Giredestrant Emerges as Breakthrough Adjuvant Therapy for Early-Stage ER-Positive Breast Cancer
Gene Therapy Revolution: Waskyra Offers Life-Changing Hope for Wiskott-Aldrich Syndrome Patients

Gene Therapy Revolution: Waskyra Offers Life-Changing Hope for Wiskott-Aldrich Syndrome Patients

A groundbreaking achievement in genetic medicine has emerged as the European Medicines Agency (EMA) recommended approval of Waskyra (etuvetidigene autotemcel), the first gene therapy specifically designed to treat Wiskott-Aldrich syndrome…

Continue Reading Gene Therapy Revolution: Waskyra Offers Life-Changing Hope for Wiskott-Aldrich Syndrome Patients
Tonix Advances Novel Oxytocin Treatment for Prader-Willi Syndrome into Clinical Testing

Tonix Advances Novel Oxytocin Treatment for Prader-Willi Syndrome into Clinical Testing

Tonix Pharmaceuticals announced plans to initiate Phase 2 clinical trials in 2026 for TNX-2900, an innovative intranasal oxytocin formulation designed to treat Prader-Willi Syndrome (PWS), a rare genetic disorder characterized…

Continue Reading Tonix Advances Novel Oxytocin Treatment for Prader-Willi Syndrome into Clinical Testing
Aldeyra Therapeutics Advances Immune Disease Pipeline Following Positive Phase 2 Results in Alcohol-Associated Hepatitis

Aldeyra Therapeutics Advances Immune Disease Pipeline Following Positive Phase 2 Results in Alcohol-Associated Hepatitis

Aldeyra Therapeutics, Inc., a biotechnology leader in immune-mediated disease therapies, has announced encouraging results from its Phase 2 clinical trial evaluating ADX-629 in patients with alcohol-associated hepatitis, and is now…

Continue Reading Aldeyra Therapeutics Advances Immune Disease Pipeline Following Positive Phase 2 Results in Alcohol-Associated Hepatitis
BridgeBio’s BBP-418 Surpasses Phase 3 Milestones, Paving Way for Muscular Dystrophy FDA Submission

BridgeBio’s BBP-418 Surpasses Phase 3 Milestones, Paving Way for Muscular Dystrophy FDA Submission

BridgeBio Pharma has reported decisive success in a pivotal phase 3 trial for its rare disease drug BBP-418, aimed at treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Reported by Fierce…

Continue Reading BridgeBio’s BBP-418 Surpasses Phase 3 Milestones, Paving Way for Muscular Dystrophy FDA Submission
Merck & Co Launches Phase IIb Trials of Tulisokibart in Rheumatoid Arthritis and Other Inflammatory Diseases

Merck & Co Launches Phase IIb Trials of Tulisokibart in Rheumatoid Arthritis and Other Inflammatory Diseases

Merck & Co has taken a significant step forward in its immunology pipeline by initiating Phase IIb clinical studies for tulisokibart (MK-7240), its investigational therapy targeting immune-mediated inflammatory diseases. According…

Continue Reading Merck & Co Launches Phase IIb Trials of Tulisokibart in Rheumatoid Arthritis and Other Inflammatory Diseases
Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases

Merck has announced a significant expansion of its clinical development program for tulisokibart (MK-7240), an investigational monoclonal antibody targeting the inflammatory mediator TL1A. Reported by Drugs.com, in October 2025, the…

Continue Reading Merck Advances Tulisokibart’s Clinical Reach: New Phase 2b Trials Target Three Immune Diseases
Updating the findings from Phase 3 DREAMM 7 trials for Relapsed/refractory Multiple Myeloma Patients

Updating the findings from Phase 3 DREAMM 7 trials for Relapsed/refractory Multiple Myeloma Patients

Lancet Oncology Recently published reports updating the findings from the phase 3 DREAMM 7 trial involving 494 patients averaging ages 64.5 years with the median follow-up of 39.4 months. Accordingly, patients…

Continue Reading Updating the findings from Phase 3 DREAMM 7 trials for Relapsed/refractory Multiple Myeloma Patients
We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.
Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Partner With Us
Submit a Story

Keep Up to Date

Subscribe to Our Newsletter
Check Out Rare Events
Get Inspired By Our Memes

Learn More

About Us
Rare Diseases and Conditions
Terms of Use
Privacy Notice
Privacy Policy for CA Residents
EU/UK Privacy Notice
Data Privacy Framework: Consumer Privacy Policy
Consumer Health Data Privacy Policy
Cookie Notice

Facebook-f Twitter Instagram Podcast Youtube Tiktok Linkedin-in Pinterest Envelope

© Copyright 2024 Patient Worthy